       Document 0269
 DOCN  M9640269
 TI    Nontuberculous mycobacterial infection in HIV-negative patients
       receiving immunosuppressive therapy.
 DT    9604
 AU    Skogberg K; Ruutu P; Tukiainen P; Valtonen VV; Department of
       Bacteriology and Immunology, University of; Helsinki, Finland.
 SO    Eur J Clin Microbiol Infect Dis. 1995 Sep;14(9):755-63. Unique
       Identifier : AIDSLINE MED/96120942
 AB    The clinical significance of nontuberculous mycobacterial isolates and
       presentation of mycobacteriosis was compared in HIV-negative patients
       with or without preceding immunosuppression. Patients with
       nontuberculous mycobacterial isolates (n = 139), mainly from the
       respiratory system, were divided into three groups: those who had had
       previous immunosuppressive treatment (24%), those with other underlying
       diseases (54%) and those without predisposing factors (22%). The
       distribution of mycobacterial species among the various patient groups
       was similar. The immunosuppressed patients fulfilled the criteria of the
       American Thoracic Society for clinical mycobacteriosis less frequently
       (18%) than those with other underlying diseases (32%) or without
       predisposing factors (45%), p = 0.07, the difference being more striking
       for patients with Mycobacterium avium complex isolates. This was partly
       due to the difficulty in distinguishing the relevant symptoms from those
       caused by the underlying disease. The proportion of patients receiving
       antimycobacterial therapy differed similarly (18%, 21%, 45%,
       respectively). Among the immunosuppressed patients, positive acid-fast
       smears were significantly less common and polymicrobial infections,
       initial lymphocytopenia, fever and fatal outcome significantly more
       common. About half of the immunosuppressed patients died within one
       year. In order to better define patients requiring treatment, the
       criteria for localized mycobacteriosis among immunosuppressed patients
       should be reevaluated.
 DE    Adult  Aged  Aged, 80 and over  Human  Immunosuppressive Agents/*ADVERSE
       EFFECTS  Middle Age  Mycobacterium/ISOLATION & PURIF  Mycobacterium
       Infections/DRUG THERAPY/*ETIOLOGY/MICROBIOLOGY  Support, Non-U.S. Gov't
       JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

